Welcome to the international HTA database

Showing [16734 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2020	NIHR Health Technology Assessment programme	Adding web-based behavioural support to exercise referral schemes for inactive adults with chronic health conditions: the e-coachER RCT
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Extracorporeal cytokine haemadsorption therapy in patients with sepsis or SIRS. Update 2020
2020	Ontario Health	Transcatheter Aortic Valve Implantation in Patients With Severe, Symptomatic Aortic Valve Stenosis at Intermediate Surgical Risk: A Health Technology Assessment
2020	Agency for Healthcare Research and Quality (AHRQ)	Management of primary headaches in pregnancy
2020	Ontario Health	Portable Normothermic Cardiac Perfusion System in Donation After Cardiocirculatory Death: A Health Technology Assessment
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Intrauterine ultrasound-guided transcervical radiofrequency ablation
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Percutaneous Transvascular Implantation of a Coronary Sinus Reducing Stent
2020	National Institute for Health and Care Excellence (NICE)	Zio XT for detecting cardiac arrhythmias. NICE medical technologies guidance 52
2020	NIHR Health Technology Assessment programme	Two speeds of increasing milk feeds for very preterm or very low-birthweight infants: the SIFT RCT
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Radiofrequency-Induced Intravesical Chemohyperthermia for Non-Muscle-Invasive Bladder Cancer
2020	National Institute for Health and Care Excellence (NICE)	SEM Scanner 200 for preventing pressure ulcers. NICE medical technologies guidance 51
2020	Ontario Health	Auditory Brainstem Implantation for Adults With Neurofibromatosis 2 or Severe Inner Ear Abnormalities: A Health Technology Assessment
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Vascular-targeted photodynamic therapy with padeliporfin (Tookad® Soluble)
2020	Scottish Health Technologies Group (SHTG)	Second-generation colon capsule endoscopy (CCE-2) for the detection of colorectal polyps – SHTG Recommendation
2020	National Institute for Health and Care Excellence (NICE)	Axonics sacral neuromodulation system for treating refractory overactive bladder. NICE medical technologies guidance 50
2020	NIHR Health Technology Assessment programme	The association between primary care quality and health-care use, costs and outcomes for people with serious mental illness: a retrospective observational study
2020	Ontario Health	Cell-Free Circulating Tumour DNA Blood Testing to Detect EGFR T790M Mutation in People With Advanced Non–Small Cell Lung Cancer: A Health Technology Assessment
2020	Scottish Health Technologies Group (SHTG)	Pre-treatment DPYD genetic testing for patients who are prescribed chemotherapy involving fluoropyrimidines – SHTG Assessment
2020	National Institute for Health and Care Excellence (NICE)	Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia. NICE medical technologies guidance 49
2020	Health Information and Quality Authority (HIQA)	Evidence summary for accuracy of molecular and antigen detection tests for the diagnosis of COVID-19 using alternative clinical specimens or sites
2020	Scottish Health Technologies Group (SHTG)	Continuous glucose monitoring in pregnant women with type 1 diabetes – SHTG Adaptation
2020	National Institute for Health and Care Excellence (NICE)	PneuX to prevent ventilator-associated pneumonia. NICE medical technologies guidance 48
2020	Health Information and Quality Authority (HIQA)	Evidence summary for the relative importance of droplet versus contact transmission to the spread of SARS-CoV-2
2020	Agency for Care Effectiveness (ACE)	Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for treating benign prostatic hyperplasia
2020	National Institute for Health and Care Excellence (NICE)	Episcissors-60 for mediolateral episiotomy. NICE medical technologies guidance 47
2020	Health Information and Quality Authority (HIQA)	Evidence summary for airborne transmission of SARS-CoV-2 via aerosols
2020	Scottish Health Technologies Group (SHTG)	Endobronchial valves for lung volume reduction in patients with severe or very severe emphysema - SHTG Recommendation
2020	Health Information and Quality Authority (HIQA)	Rapid review of public health guidance on universal face mask use by healthcare workers in the context of COVID-19
2020	Agency for Care Effectiveness (ACE)	Direct-acting antiviral agents for treating genotype 1 chronic hepatitis C
2020	Agency for Healthcare Research and Quality (AHRQ)	No-touch modalities for disinfecting patient rooms in acute care settings: a rapid review
2020	Health Information and Quality Authority (HIQA)	Evidence summary for universal face mask use by healthcare workers in the context of COVID-19
2020	Health Information and Quality Authority (HIQA)	Evidence summary for non-contact thermal screening as an effective means of identifying cases of COVID-19
2020	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Kaiku Health Service for symptom management of cancer patients
2020	Health Information and Quality Authority (HIQA)	Review of international public policy responses to easing restrictions introduced to limit the spread of COVID-19
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Covid-19: HSS/ Horizon Scanning Living Document (v01 April 2020) Part 1; Covid-19: HSS/ Horizon Scanning Living Document (v01 April 2020) Part 2 (Appendix)
2020	Agency for Care Effectiveness (ACE)	Direct-acting antiviral agents for treating genotype 2 to 6 chronic hepatitis C
2020	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Indego Exoskeleton for walking rehabilitation
2020	Health Information and Quality Authority (HIQA)	Analysis of excess all-cause mortality in Ireland during the COVID-19 epidemic
2020	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Lokomat robot for walking rehabilitation
2020	Agency for Healthcare Research and Quality (AHRQ)	Nonopioid pharmacologic treatments for chronic pain
2020	Health Information and Quality Authority (HIQA)	Scoping report: universal influenza vaccination in children
2020	Health Information and Quality Authority (HIQA)	Rapid review of public health guidance on physical distancing in the context of COVID-19
2020	Health Information and Quality Authority (HIQA)	Evidence summary for accuracy of salivary samples in SARS-CoV-2 detection compared with nasopharyngeal, oropharyngeal or lower respiratory tract samples
2020	Agency for Healthcare Research and Quality (AHRQ)	Opioid treatments for chronic pain
2020	Health Information and Quality Authority (HIQA)	Scoping evidence summary for surgical outcomes in patients with COVID-19
2020	Health Information and Quality Authority (HIQA)	Evidence summary for SARS-CoV-2 viral load and infectivity over the course of an infection
2020	NIHR Health Technology Assessment programme	Antimicrobial-impregnated central venous catheters for preventing neonatal bloodstream infection: the PREVAIL RCT
2020	Agency for Care Effectiveness (ACE)	Pulmonary surfactant for treating respiratory distress syndrome in premature infants
2020	Health Information and Quality Authority (HIQA)	Evidence summary for aerosol generating procedures: risk of transmission of SARS-CoV-2 from patients without clinical symptoms
2020	Ontario Health	10-kHz high-frequency spinal cord stimulation for adults with chronic noncancer pain: a health technology assessment
2020	Health Information and Quality Authority (HIQA)	Evidence summary for care pathways support for the resumption of scheduled hospital care in the context of COVID-19
2020	Ontario Health	Continual Long-Term Physiotherapy After Stroke: A Health Technology Assessment
2020	Agency for Care Effectiveness (ACE)	Ursodeoxycholic acid for treating primary biliary cirrhosis
2020	Ontario Health	Extracorporeal Membrane Oxygenation for Cardiac Indications in Adults: A Health Technology Assessment
2020	Adelaide Health Technology Assessment (AHTA)	Discussion paper on pan-tumour biomarker testing to determine eligibility for targeted treatment.
2020	Ontario Health	5-Aminolevulinic Acid Hydrochloride (5 ALA)–Guided Surgical Resection of High-Grade Gliomas: A Health Technology Assessment
2020	Adelaide Health Technology Assessment (AHTA)	Serious adverse events associated with yellow fever vaccination
2020	Ontario Health	Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment
2020	Adelaide Health Technology Assessment (AHTA)	Serious adverse events associated with oral cholera vaccination
2020	Ontario Health	Genome-Wide Sequencing for Unexplained Developmental Disabilities or Multiple Congenital Anomalies: A Health Technology Assessment
2020	Agency for Healthcare Research and Quality (AHRQ)	Prevention, diagnosis, and management of opioids, opioid misuse, and opioid use disorder in older adults
2020	Health Technology Wales (HTW)	The clinical effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis
2020	Agency for Care Effectiveness (ACE)	Intravenous proton pump inhibitors for gastric anti-secretory treatment when oral therapies are unsuitable
2020	National Institute for Health and Care Excellence (NICE)	Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure. NICE technology appraisal guidance 617
2020	Agency for Care Effectiveness (ACE)	Budesonide prolonged-release tablet for treating mild to moderate active ulcerative colitis
2020	Agency for Healthcare Research and Quality (AHRQ)	Resource allocation and pandemic response: an evidence synthesis to inform decision making
2020	National Institute for Health and Care Excellence (NICE)	Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 618
2020	NIHR Health Technology Assessment programme	Basic versus biofeedback-mediated intensive pelvic floor muscle training for women with urinary incontinence: the OPAL RCT
2020	Agency for Care Effectiveness (ACE)	Epoprostenol for treating pulmonary arterial hypertension
2020	Agency for Healthcare Research and Quality (AHRQ)	Retention strategies for medications for addiction treatment in adults with opioid use disorder
2020	National Institute for Health and Care Excellence (NICE)	Sotagliflozin with insulin for treating type 1 diabetes. NICE technology appraisal guidance 622
2020	NIHR Health Technology Assessment programme	Positron emission tomography to image cerebral neuroinflammation in ischaemic stroke: a pilot study
2020	Agency for Care Effectiveness (ACE)	Vonoprazan for treating helicobacter pylori infection
2020	National Institute for Health and Care Excellence (NICE)	Patiromer for treating hyperkalaemia. NICE technology appraisal guidance 623
2020	Agency for Care Effectiveness (ACE)	Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia
2020	National Institute for Health and Care Excellence (NICE)	Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 624
2020	Agency for Care Effectiveness (ACE)	Trastuzumab for treating HER2-positive breast and gastric cancers
2020	National Institute for Health and Care Excellence (NICE)	Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal). NICE technology appraisal guidance 625
2020	Agency for Care Effectiveness (ACE)	Antiretroviral therapies for treating human immunodeficiency virus type 1 (HIV-1) infection
2020	National Institute for Health and Care Excellence (NICE)	Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure. NICE technology appraisal guidance 626
2020	Agency for Care Effectiveness (ACE)	Benralizumab, mepolizumab and omalizumab for treating severe asthma
2020	National Institute for Health and Care Excellence (NICE)	Lenalidomide with rituximab for previously treated follicular lymphoma. NICE technology appraisal guidance 627
2020	NIHR Health Technology Assessment programme	Dementia Care Mapping to reduce agitation in care home residents with dementia: the EPIC cluster RCT
2020	NIHR Health Services and Delivery Research programme	Understanding and improving experiences of care in hospital for people living with dementia, their carers and staff: three systematic reviews
2020	Agency for Care Effectiveness (ACE)	Mycophenolate mofetil for immunosuppression
2020	Agency for Healthcare Research and Quality (AHRQ)	Strategies for patient, family, and caregiver engagement
2020	National Institute for Health and Care Excellence (NICE)	Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 628
2020	Agency for Care Effectiveness (ACE)	Adalimumab for treating inflammatory conditions
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Paediatric cardiac surgery - literature review
2020	National Institute for Health and Care Excellence (NICE)	Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab. NICE technology appraisal guidance 629
2020	NIHR Health Technology Assessment programme	Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCT
2020	Agency for Care Effectiveness (ACE)	Abiraterone for treating metastatic prostate cancer
2020	National Institute for Health and Care Excellence (NICE)	Larotrectinib for treating NTRK fusion-positive solid tumours. NICE technology appraisal guidance 630
2020	National Institute for Health and Care Excellence (NICE)	Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer. NICE technology appraisal guidance 632
2020	National Institute for Health and Care Excellence (NICE)	Ustekinumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 633
2020	NIHR Health Technology Assessment programme	Stratified Care for Patients with Sciatica and Suspected Sciatica in Primary Care: a randomised trial (the SCOPiC trial - SCiatica Outcomes in Primary Care)
2020	NIHR Health Technology Assessment programme	Medically unexplained symptoms(MUS): primary care intervention
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Effectiveness of Music Therapy for Autism Spectrum Disorder, Dementia, Depression, Insomnia and Schizophrenia
2020	National Institute for Health and Care Excellence (NICE)	Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal). NICE technology appraisal guidance 634
2020	Agency for Healthcare Research and Quality (AHRQ)	Therapies for clinically localized prostate cancer